The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Canakinumab Effective as First-Line Drug for Systemic Juvenile Idiopathic Arthritis Without Steroids
VIENNA — The interleukin 1 receptor antagonist (IL-1RA) canakinumab provided control of systemic juvenile idiopathic arthritis (sJIA) without the use of glucocorticoids for up to a year in most study ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven
The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic ...
An international team of investigators today announced promising data from a trial of a novel antibiotic that could ...
2024 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Middle East Daily-- New research on Heart Disorders and Diseases - Heart Attack is the subject of a report. According to news reporting ...
BARCELONA -- Rheumatoid arthritis (RA) patients were exceedingly unlikely to develop refractory disease when their first medical therapy was a tumor necrosis factor (TNF) inhibitor, a researcher ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback